Palatin Technologies, Inc. (PTNT)

OTCMKTS · Delayed Price · Currency is USD
0.0975
+0.0155 (18.90%)
May 9, 2025, 4:00 PM EDT
Market Cap 2.42M
Revenue (ttm) 350.00K
Net Income (ttm) -26.95M
Shares Out n/a
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,364,134
Average Volume 3,034,255
Open 0.1000
Previous Close 0.0820
Day's Range 0.0821 - 0.1081
52-Week Range n/a
Beta n/a
RSI n/a
Earnings Date May 14, 2025

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]

Industry Other
Founded 1986
Employees 30
Stock Exchange OTCMKTS
Ticker Symbol PTNT
Full Company Profile

Financial Performance

In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.

Financial Statements

News

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory...

22 hours ago - PRNewsWire

Palatin Technologies Announces Closing of Reduced Public Offering

Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing fir...

1 day ago - PRNewsWire

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company...

2 days ago - PRNewsWire